CD274 and non-small cell lung carcinoma: The phase II ARC-10 study (NCT04736173) is currently evaluating the zimberelimab/domvanalimab combination versus pembrolizumab alone in locally advanced NSCLC or mNSCLC, not pretreated, with PD-L1 > 50% and without targetable oncogenic addiction.